|
0
|
|
Weekly pulmonary delivery of beta-glucan-chitosan-poly(lactic co-glycolic) acid (beta-C-P) nanoparticles with daily standard oral therapy achieves control of Mycobacterium tuberculosis in BALB/c mice.
(journals.asm.org)
|
Kutscher HL
…
Reynolds JL
Antimicrobial Agents and Chemotherapy
2026-06-03
|
#amr
#nanoparticles
#drug delivery
#pulmonary
#tb
|
|
0
|
|
Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model.
(journals.asm.org)
|
Cummings JE
…
Slayden RA
Antimicrobial Agents and Chemotherapy
2026-06-03
|
#modeling
#infection
#amr
#tb
|
|
0
|
|
Bedaquiline reloading strategies following interruptions during daily dosing.
(journals.asm.org)
|
Kikstra N
…
Koele SE
Antimicrobial Agents and Chemotherapy
2026-06-03
|
#pharmacokinetics
#modeling
#amr
#tb
|
|
0
|
|
CRISPRi-mediated in vivo gene silencing: a tool for prioritizing drug targets in Mycobacterium abscessus.
(journals.asm.org)
|
Gupta R
…
Rohde KH
Antimicrobial Agents and Chemotherapy
2026-06-03
|
#infection
#virulence
#crispr
#drug targets
#tb
|
|
0
|
|
Strain diversity drives heterogeneous responses to tuberculosis combination therapy.
(journals.asm.org)
|
Yoon MH
…
Aldridge BB
Antimicrobial Agents and Chemotherapy
2026-06-03
|
#amr
#metabolism
#synergy
#phenotyping
#tb
|